Proteomics advances for precision therapy in ovarian cancer

References

• Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384(9951):1376–1388.
   PubMed Web of Science ®Google Scholar
• Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093.
   PubMedGoogle Scholar
• Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Berger AC, Korkut A, Kanchi RS, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell. 2018;33(4):690–705 e9.
   PubMed Web of Science ®Google Scholar
• Peng G, Mills GB. Surviving ovarian cancer: an affair between defective DNA repair and RB1. Clin Cancer Res. 2018;24(3):508–510.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulos L, Prassas I, Diamandis EP, et al. Onco-proteogenomics: multi-omics level data integration for accurate phenotype prediction. Crit Rev Clin Lab Sci. 2017;54(6):414–432.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulos L, Prassas I, Diamandis EP, et al. Proteogenomics: opportunities and caveats. Clin Chem. 2016;62(4):551–557.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019;4(6):e126908.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28(22):3570–3576.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Moore DH 2nd, Ginzinger DG, et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res. 2000;60(19):5382–5385.
   PubMed Web of Science ®Google Scholar
• Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21(1):99–102.
   PubMed Web of Science ®Google Scholar
• Eder AM, Sui X, Rosen DG, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(35):12519–12524.
   PubMed Web of Science ®Google Scholar
• Nanjundan M, Nakayama Y, Cheng KW, et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007;67(7):3074–3084.
   PubMed Web of Science ®Google Scholar
• Chaluvally-Raghavan P, Jeong KJ, Pradeep S, et al. Direct upregulation of STAT3 by microRNA-551b-3p deregulates growth and metastasis of ovarian cancer. Cell Rep. 2016;15(7):1493–1504.
   PubMed Web of Science ®Google Scholar
• Nanjundan M, Cheng KW, Zhang F, et al. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol. 2008;2(2):164–181.
   PubMed Web of Science ®Google Scholar
• Yang JY, Yoshihara K, Tanaka K, et al. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest. 2013;123(9):3740–3750.
   PubMed Web of Science ®Google Scholar
• Chao A, Lai CH, Wang TH, et al. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma. J Mol Med (Berl). 2018;96(6):527–536.
   PubMed Web of Science ®Google Scholar
• Ashley CW, Da Cruz Paula A, Kumar R, et al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecol Oncol. 2019;152(1):11–19.
   PubMed Web of Science ®Google Scholar
• Peng G, Chun-Jen Lin C, Mo W, et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun. 2014;5:3361.
   PubMed Web of Science ®Google Scholar
• Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23(1):239–254 e6.
   PubMed Web of Science ®Google Scholar
• Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776–1782.
   PubMed Web of Science ®Google Scholar
• Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227–232.
   PubMed Web of Science ®Google Scholar
• Goncalves E, Fragoulis A, Garcia-Alonso L, et al. Widespread post-transcriptional attenuation of genomic copy-number variation in cancer. Cell Syst. 2017;5(4):386–398 e4.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu T, Zhang Z, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016;166(3):755–765.
   PubMed Web of Science ®Google Scholar
• Akbani R, Ng PK, Werner HM, et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014;5:3887.
   PubMed Web of Science ®Google Scholar
• Zhao W, Li J, Akbani R, et al. Credentialing individual samples for proteogenomic analysis. Mol Cell Proteomics. 2018;17(8):1515–1530.
   PubMed Web of Science ®Google Scholar
• Mertins P, Yang F, Liu T, et al. Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014;13(7):1690–1704.
   PubMed Web of Science ®Google Scholar
• Tanhaei S, Nikpour P, Ghaedi K, et al. RNA/protein discordant expression of Fndc5 in central nervous system is likely to be mediated through microRNAs. DNA Cell Biol. 2018;37(4):373–380.
   PubMed Web of Science ®Google Scholar
• Johansson HJ, Socciarelli F, Vacanti NM, et al. Breast cancer quantitative proteome and proteogenomic landscape. Nat Commun. 2019;10(1):1600.
   PubMed Web of Science ®Google Scholar
• Carey MS, Agarwal R, Gilks B, et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res. 2010;16(10):2852–2860.
   PubMed Web of Science ®Google Scholar
• Akbani R, Becker KF, Carragher N, et al. Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. Mol Cell Proteomics. 2014;13(7):1625–1643.
   PubMed Web of Science ®Google Scholar
• Lu Y, Ling S, Hegde AM, et al. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol. 2016;43(4):476–483.
   PubMed Web of Science ®Google Scholar
• Labrie M, Kim TB, Ju Z, et al. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019;10(37):3533–3546.
   PubMedGoogle Scholar
• Le T, Faught W, Hopkins L, et al. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer. J Obstet Gynaecol Can. 2008;30(8):665–670.
   PubMedGoogle Scholar
• Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, et al. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. Int J Gynecol Cancer. 2011;21(6):1013–1017.
   PubMed Web of Science ®Google Scholar
• Cai RL, Yan-Neale Y, Cueto MA, et al. HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins. J Biol Chem. 2000;275(36):27909–27916.
   PubMed Web of Science ®Google Scholar
• Yu KH, Levine DA, Zhang H, et al. Predicting ovarian cancer patients’ clinical response to platinum-based chemotherapy by their tumor proteomic signatures. J Proteome Res. 2016;15(8):2455–2465.
   PubMed Web of Science ®Google Scholar
• Peng X, Xu X, Wang Y, et al. A-to-I RNA editing contributes to proteomic diversity in cancer. Cancer Cell. 2018;33(4):817–828 e7.
   PubMedGoogle Scholar
• Gonzalez VD, Samusik N, Chen TJ, et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep. 2018;22(7):1875–1888.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628.
   PubMed Web of Science ®Google Scholar
• Hammerlindl H, Schaider H. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. J Cell Commun Signal. 2018;12(1):133–141.
   PubMed Web of Science ®Google Scholar
• Emmons MF, Faiao-Flores F, Smalley KSM. The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem Pharmacol. 2016;122:1–9.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726.
   PubMed Web of Science ®Google Scholar
• Sun C, Fang Y, Yin J, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017;9(392).
   Web of Science ®Google Scholar
• Choi JI, Park SH, Lee HJ, et al. Inhibition of phospho-S6 kinase, a protein involved in the compensatory adaptive response, increases the efficacy of paclitaxel in reducing the viability of matrix-attached ovarian cancer cells. PLoS One. 2016;11(5):e0155052.
   PubMed Web of Science ®Google Scholar
• Fang P, Madden JA, Neums L, et al. Olaparib-induced adaptive response is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition. Mol Cancer Res. 2018;16(6):961–973.
   PubMed Web of Science ®Google Scholar
• Fang Y, McGrail DJ, Sun C, et al. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell. 2019;35(6):851–867 e7.
   PubMed Web of Science ®Google Scholar
• Hew KE, Miller PC, El-Ashry D, et al. MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian cancer. Clin Cancer Res. 2016;22(4):935–947.
   PubMed Web of Science ®Google Scholar
• Iavarone C, Zervantonakis IK, Selfors LM, et al. Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness. Mol Cancer Ther. 2019;18(3):642–655.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20(4):570–580.
   PubMed Web of Science ®Google Scholar
• Liu JF, Tolaney SM, Birrer M, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49(14):2972–2978.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Wulf GM, Barry WT, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017;28(3):512–518.
   PubMed Web of Science ®Google Scholar
• Sun C, Yin J, Fang Y, et al. BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell. 2018;33(3):401–416 e8.
   PubMed Web of Science ®Google Scholar
• Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–156.
   PubMed Web of Science ®Google Scholar
• Lee HH, Bellat V, Law B. Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer. PLoS One. 2017;12(2):e0171044.
   PubMed Web of Science ®Google Scholar
• Shen L, Sun B, Sheng J, et al. PGC1alpha promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis. Int J Oncol. 2018;53(1):404–416.
   PubMed Web of Science ®Google Scholar
• Amoroso MR, Matassa DS, Agliarulo I, et al. Stress-adaptive response in ovarian cancer drug resistance: role of TRAP1 in oxidative metabolism-driven inflammation. Adv Protein Chem Struct Biol. 2017;108:163–198.
   PubMed Web of Science ®Google Scholar
• Reinthaller A. Antiangiogenic therapies in ovarian cancer. Memo. 2016;9(3):139–143.
   PubMedGoogle Scholar
• Previs RA, Armaiz-Pena GN, Ivan C, et al. Role of YAP1 as a marker of sensitivity to dual AKT and P70S6K inhibition in ovarian and uterine malignancies. J Natl Cancer Inst. 2017;109(7). Online ID: djw296.
   PubMedGoogle Scholar
• Yang X, Shen F, Hu W, et al. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015;27(1):58–65.
   PubMed Web of Science ®Google Scholar
• Lyons YA, Pradeep S, Wu SY, et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017;8(57):96496–96505.
   PubMedGoogle Scholar
• Kurimchak AM, Shelton C, Duncan KE, et al. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 2016;16(5):1273–1286.
   PubMed Web of Science ®Google Scholar
• Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther. 2017;10:5195–5208.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158.
   PubMed Web of Science ®Google Scholar
• Pilie PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.
   PubMed Web of Science ®Google Scholar
• Vanderstichele A, Busschaert P, Olbrecht S, et al. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. Eur J Cancer. 2017;86:5–14.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599.
   PubMed Web of Science ®Google Scholar
• Shen Y, Aoyagi-Scharber M, Wang B. Trapping poly(ADP-ribose) polymerase. J Pharmacol Exp Ther. 2015;353(3):446–457.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433–443.
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036–1047.
   PubMed Web of Science ®Google Scholar
• Vena F, Jia R, Esfandiari A, et al. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget. 2018;9(14):11592–11603.
   PubMedGoogle Scholar
• Chen M-J, Li J, Akbani R, et al. TCPA v6.0: an integrative platform for pan-cancer analysis of functional proteomic data. Mol Cell Proteomics. 2019. In press.
   Web of Science ®Google Scholar
• Chen MM, Li J, Wang Y, et al. TCPA v3.0: an integrative platform to explore the pan-cancer analysis of functional proteomic data. Mol Cell Proteomics. 2019;18:S15–S25.
   Web of Science ®Google Scholar
• Grote T, Siwak DR, Fritsche HA, et al. Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics. 2008;8(15):3051–3060.
   PubMed Web of Science ®Google Scholar
• Lee J, Geiss GK, Demirkan G, et al. Implementation of a multiplex and quantitative proteomics platform for assessing protein lysates Using DNA-barcoded antibodies. Mol Cell Proteomics. 2018;17(6):1245–1258.
   PubMed Web of Science ®Google Scholar
• Li J, Lu Y, Akbani R, et al. TCPA: a resource for cancer functional proteomics data. Nat Methods. 2013;10(11):1046–1047.
   PubMed Web of Science ®Google Scholar
• Cohen AA, Geva-Zatorsky N, Eden E, et al. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008;322(5907):1511–1516.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428.
   PubMed Web of Science ®Google Scholar
• Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell. 2008;14(2):111–122.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69–80.
   PubMed Web of Science ®Google Scholar
• Lin JR, Fallahi-Sichani M, Chen JY, et al. Cyclic Immunofluorescence (CycIF), a highly multiplexed method for single-cell imaging. Curr Protoc Chem Biol. 2016;8(4):251–264.
   PubMedGoogle Scholar
• Tsujikawa T, Kumar S, Borkar RN, et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 2017;19(1):203–217.
   PubMed Web of Science ®Google Scholar
• Keren L, Bosse M, Marquez D, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373–1387 e19.
   PubMed Web of Science ®Google Scholar
• Lin JR, Fallahi-Sichani M, Sorger PK. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. Nat Commun. 2015;6:8390.
   PubMed Web of Science ®Google Scholar
• Eng JG, Luoh S, Gray J, et al. Cyclic multiplexed-immunofluorescence (cmIF), a highly multiplexed method for single-cell analysis, in biomarkers for immunotherapy of cancer. Methods Mol Biol. 2019;2055. [In press].
   Google Scholar
• Faria SS, Morris CF, Silva AR, et al. A timely shift from shotgun to targeted proteomics and how it can be groundbreaking for cancer research. Front Oncol. 2017;7:13.
   PubMed Web of Science ®Google Scholar
• Zhang B, Whiteaker JR, Hoofnagle AN, et al. Clinical potential of mass spectrometry-based proteogenomics. Nat Rev Clin Oncol. 2019;16(4):256–268.
   PubMed Web of Science ®Google Scholar
• Chang CY, Picotti P, Huttenhain R, et al. Protein significance analysis in selected reaction monitoring (SRM) measurements. Mol Cell Proteomics. 2012;11(4):M111 014662.
   PubMed Web of Science ®Google Scholar
• Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11(6):O111 016717.
   PubMed Web of Science ®Google Scholar
• Ludwig C, Gillet L, Rosenberger G, et al. Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial. Mol Syst Biol. 2018;14(8):e8126.
   PubMed Web of Science ®Google Scholar